Therapeutic indications

Alemtuzumab is indicated for:

Relapsing remitting multiple sclerosis (RRMS)

Population group: both men and women, only adults (18 years old or older)

Alemtuzumab is indicated as a single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the following patient groups:

  • Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or
  • Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

For this indication, competent medicine agencies globally authorize below treatments (click for details):


Alemtuzumab is contraindicated in the following cases:

Human Immunodeficiency Virus (HIV) infection

Human immunodeficiency virus infection



Severe active infection

Infectious disease




High blood pressure

Arterial dissection of the cervicocephalic arteries

Dissection of cervicocerebral artery


at least one of
CVA - Cerebrovascular accident


Angina pectoris, myocardial infarction

at least one of
H/O: angina pectoris


Myocardial infarction

Past history of myocardial infarction

Coagulopathy, anti-platelets, anti-coagulants

at least one of
Blood coagulation disorder

Antithrombotic agents

Concomitant autoimmune diseases

Autoimmune disease
and additionally not
Relapsing remitting multiple sclerosis

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines